Martínez Bedoya D, Dutoit V, Migliorini D. Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma. Front Immunol. 2021;12: 640082. https://doi.org/10.3389/fimmu.2021.640082.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106–15. https://doi.org/10.1158/1078-0432.CCR-06-1183.

Article  CAS  PubMed  PubMed Central  Google Scholar 

June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361–5. https://doi.org/10.1126/science.aar6711.

Article  CAS  PubMed  Google Scholar 

Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017;16:669. https://doi.org/10.1038/nrd.2017.196.

Article  CAS  PubMed  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.

Article  CAS  PubMed  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.

Article  PubMed  Google Scholar 

Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594–606. https://doi.org/10.1200/JCO.22.01797.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. Lancet (London, England). 2023;402(10402):641–54. https://doi.org/10.1016/S0140-6736(23)01052-8.

Article  CAS  PubMed  Google Scholar 

Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, et al. Safety and efficacy of standard of care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2024. https://doi.org/10.1182/blood.2024025945.

Article  PubMed  Google Scholar 

Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–48. https://doi.org/10.1038/s41591-018-0036-4.

Article  CAS  PubMed  Google Scholar 

Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4–1BB costimulatory domains. Nat Rev Clin Oncol. 2021;18(11):715–27. https://doi.org/10.1038/s41571-021-00530-z.

Article  CAS  PubMed  Google Scholar 

Zhao X, Yang J, Zhang X, et al. Efficacy and safety of CD28- or 4–1BB-based CD19 CAR-T cells in B cell acute lymphoblastic leukemia. Mol Therapy Oncol. 2020;18:272–81. https://doi.org/10.1016/j.omto.2020.06.016.

Article  CAS  Google Scholar 

Gordon S, Plüddemann A. The mononuclear phagocytic system. Generation of diversity. Front Immunol. 2019;10:1893. https://doi.org/10.3389/fimmu.2019.01893.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lavin Y, Mortha A, Rahman A, Merad M. Regulation of macrophage development and function in peripheral tissues. Nat Rev Immunol. 2015;15(12):731–44. https://doi.org/10.1038/nri3920.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faria AMC, Reis BS, Mucida D. Tissue adaptation: implications for gut immunity and tolerance. J Exp Med. 2017;214(5):1211–26. https://doi.org/10.1084/jem.20162014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, et al. Macrophages facilitate electrical conduction in the heart. Cell. 2017;169(510–22): e20. https://doi.org/10.1016/j.cell.2017.03.050.

Article  CAS  Google Scholar 

van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen: differential kinetics after liposome-mediated elimination. J Leukoc Biol. 1989;45(2):97–104. https://doi.org/10.1002/jlb.45.2.97.

Article  PubMed  Google Scholar 

Opperman KS, Vandyke K, Clark KC, et al. Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo. Neoplasia. 2019;21(8):777–87. https://doi.org/10.1016/j.neo.2019.05.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur J Pharmacol. 2020;877: 173090. https://doi.org/10.1016/j.ejphar.2020.173090.

Article  CAS  PubMed  Google Scholar 

Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. https://doi.org/10.1016/j.bbmt.2018.12.758.

Article  CAS  PubMed  Google Scholar 

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–47. https://doi.org/10.1056/NEJMoa1609783.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Therapy. 2017;25:285–95.

Article  CAS  Google Scholar 

Garcia Borrega J, Gödel P, Rüger MA, et al. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019;3(2): e191. https://doi.org/10.1097/HS9.0000000000000191.

Article  PubMed  PubMed Central  Google Scholar 

Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematol Am Soc Hematol Educ Program. 2013;2013:605–11. https://doi.org/10.1182/asheducation-2013.1.605.

Article  Google Scholar 

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. https://doi.org/10.1186/s40425-018-0343-9.

Article  PubMed  PubMed Central  Google Scholar 

Matthys P, Dillen C, Proost P, Heremans H, Van Damme J, Billiau A. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur J Immunol. 1993;23(9):2209–16. https://doi.org/10.1002/eji.1830230924.

Article  CAS  PubMed  Google Scholar 

Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19. https://doi.org/10.1158/2159-8290.CD-17-0698.

Article